Biogen Announces First Patient Dosed with BIIB059 in Phase 3 Systemic Lupus Erythematosus Study

Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE), a debilitating autoimmune disease which has limited treatment...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials